158 related articles for article (PubMed ID: 24266618)
1. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs.
Frączek T; Siwek A; Paneth P
J Chem Inf Model; 2013 Dec; 53(12):3326-42. PubMed ID: 24266618
[TBL] [Abstract][Full Text] [Related]
2. Searching for novel scaffold of triazole non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Frączek T; Paneth A; Kamiński R; Krakowiak A; Paneth P
J Enzyme Inhib Med Chem; 2016; 31(3):481-9. PubMed ID: 25942362
[TBL] [Abstract][Full Text] [Related]
3. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
4. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase.
Carlsson J; Boukharta L; Aqvist J
J Med Chem; 2008 May; 51(9):2648-56. PubMed ID: 18410085
[TBL] [Abstract][Full Text] [Related]
5. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
6. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of sporolides A and B from Salinispora tropica: in silico target prediction using ligand-based pharmacophore mapping and in vitro activity validation on HIV-1 reverse transcriptase.
Dineshkumar K; Aparna V; Madhuri KZ; Hopper W
Chem Biol Drug Des; 2014 Mar; 83(3):350-61. PubMed ID: 24165098
[TBL] [Abstract][Full Text] [Related]
8. Unconventional plasticity of HIV-1 reverse transcriptase: how inhibitors could open a connection "gate" between allosteric and catalytic sites.
Bellucci L; Angeli L; Tafi A; Radi M; Botta M
J Chem Inf Model; 2013 Dec; 53(12):3117-22. PubMed ID: 24256065
[TBL] [Abstract][Full Text] [Related]
9. Towards a MIP-based alignment and docking in computer-aided drug design.
Barbany M; Gutiérrez-de-Terán H; Sanz F; Villà-Freixa J
Proteins; 2004 Aug; 56(3):585-94. PubMed ID: 15229890
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Sivan SK; Manga V
J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
[TBL] [Abstract][Full Text] [Related]
11. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
Zhan P; Li X; Li Z; Chen X; Tian Y; Chen W; Liu X; Pannecouque C; De Clercq E
Bioorg Med Chem Lett; 2012 Dec; 22(23):7155-62. PubMed ID: 23084898
[TBL] [Abstract][Full Text] [Related]
12. Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets.
Xu W; Lucke AJ; Fairlie DP
J Mol Graph Model; 2015 Apr; 57():76-88. PubMed ID: 25682361
[TBL] [Abstract][Full Text] [Related]
13. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
[TBL] [Abstract][Full Text] [Related]
14. Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Wu HQ; Yan ZH; Chen WX; He QQ; Chen FE; De Clercq E; Balzarini J; Daelemans D; Pannecouque C
Bioorg Med Chem; 2013 Nov; 21(21):6477-83. PubMed ID: 24055077
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Xiaohe Z; Yu Q; Hong Y; Xiuqing S; Rugang Z
Chem Biol Drug Des; 2010 Oct; 76(4):330-9. PubMed ID: 20731670
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Li D; Zhan P; Liu H; Pannecouque C; Balzarini J; De Clercq E; Liu X
Bioorg Med Chem; 2013 Apr; 21(7):2128-34. PubMed ID: 23415090
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design.
Zhan P; Chen X; Li D; Fang Z; De Clercq E; Liu X
Med Res Rev; 2013 Jun; 33 Suppl 1():E1-72. PubMed ID: 21523792
[TBL] [Abstract][Full Text] [Related]
18. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
Sengupta D; Verma D; Naik PK
In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
[TBL] [Abstract][Full Text] [Related]
19. Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening.
Shiri F; Pirhadi S; Rahmani A
J Recept Signal Transduct Res; 2018 Feb; 38(1):37-47. PubMed ID: 29254400
[TBL] [Abstract][Full Text] [Related]
20. Theoretical studies of energetics and binding isotope effects of binding a triazole-based inhibitor to HIV-1 reverse transcriptase.
Krzemińska A; Świderek KP; Paneth P
Phys Chem Chem Phys; 2016 Jan; 18(1):310-7. PubMed ID: 26612030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
